Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study

2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)

(2011) et al.   CIRCULATION

Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions

(2011) A L Beitelshees et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

(2011) S A Scott et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting

(2011) H. J. Bouman et al.   HEART

Clopidogrel and Proton Pump Inhibitors

(2011) Udaya S. Tantry et al.   JACC-Cardiovascular Interventions

Clopidogrel–Drug Interactions

(2011) Eric R. Bates et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention

(2011) Gianluca Campo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention

(2011) Orsolya Rideg et al.   PHARMACOGENOMICS

Do structural differences in statins correlate with clinical efficacy?

(2010) Lorenzo Arnaboldi et al.   CURRENT OPINION IN LIPIDOLOGY

Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day

(2010) Young-Hoon Jeong et al.   JACC-Cardiovascular Interventions

The Effect of St Johnʼs Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity

(2010) Wei C Lau et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate

(2010) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay

(2010) In-Suk Kim et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

(2010) Jessica L Mega et al.   LANCET

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

(2010) Lars Wallentin et al.   LANCET

Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs

(2009) Ferhana Y. Ali et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

(2009) M. Kazui et al.   DRUG METABOLISM AND DISPOSITION

Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans

(2009) Nagy A. Farid et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacogenetics and Potential Application in Personalized Medicine

(2008) Shu-Feng Zhou et al.   CURRENT DRUG METABOLISM

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

(2008) Spencer B. King et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY